Â鶹ѧÉú¾«Æ·°æ

Luke Maese
No Rating Available
(Learn About Our Rating System)

Luke Maese, DO

Languages spoken: English

Clinical Locations

Primary Children's Hospital

Pediatric Hematology/Oncology
Salt Lake City
801-662-4700

  • Luke Maese, D.O., received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Pediatric residency at UPMC Children’s Hospital of Pittsburgh and Pediatric Hematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital. He joined the faculty of the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology in 2015 where he currently serves as an Associate Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).

    Dr. Maese’s focus includes clinical care for children with malignant hematopoietic disorders and cancer predisposition syndromes. He serves as director for the pediatric Leukemia/Lymphoma and pediatric Cancer Genetics programs, as well as the director of the Clinical Trial Research Enterprise and co-Director of the Bone Marrow Failure program within the division of pediatric hematology/oncology at PCH. He is a member of the Family Cancer Assessment Clinic (FCAC) and of the Schiffman lab at HCI.

    Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trial development in pediatric acute lymphoblastic leukemia. He is a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

    For questions regarding Dr. Maese's family cancer assessment clinic practice at the Huntsman Cancer Institute please contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-9555 or go to Family History of Cancer | Huntsman Cancer Institute | Â鶹ѧÉú¾«Æ·°æ for more information.

    .
    For questions regarding Dr. Maese's pediatric practice and the Leukemia/Lymphoma Program at Primary Children's Medical Center, please call (801) 662-4700.

    Specialties

    Board Certification

    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Luke Maese, D.O., received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Pediatric residency at UPMC Children’s Hospital of Pittsburgh and Pediatric Hematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital. He joined the faculty of the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology in 2015 where he currently serves as an Associate Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).

    Dr. Maese’s focus includes clinical care for children with malignant hematopoietic disorders and cancer predisposition syndromes. He serves as director for the pediatric Leukemia/Lymphoma and pediatric Cancer Genetics programs, as well as the director of the Clinical Trial Research Enterprise and co-Director of the Bone Marrow Failure program within the division of pediatric hematology/oncology at PCH. He is a member of the Family Cancer Assessment Clinic (FCAC) and of the Schiffman lab at HCI.

    Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trial development in pediatric acute lymphoblastic leukemia. He is a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

    For questions regarding Dr. Maese's family cancer assessment clinic practice at the Huntsman Cancer Institute please contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-9555 or go to Family History of Cancer | Huntsman Cancer Institute | Â鶹ѧÉú¾«Æ·°æ for more information.

    .
    For questions regarding Dr. Maese's pediatric practice and the Leukemia/Lymphoma Program at Primary Children's Medical Center, please call (801) 662-4700.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Fellowship Pediatric Hematology/Oncology - University of Utah Fellow
    Residency Pediatrics - Children’s Hospital of Pittsburgh of UPMC Resident
    Professional Medical Osteopathic Medicine - Kansas City University of Medicine and Biosciences D.O.
    Undergraduate Human Biology - University of Kansas B.G.S.

    Selected Publications

    Journal Article

    1. Maese LD, Wlodarski MW, Kim SY, Bertuch AA, Bougeard G, Chang VY, Godley LA, Khincha PP, Kuiper RP, Lesmana H, McGee RB, McReynolds LJ, Meade J, Plon SE, Savage SA, Scollon SR, Scott HS, Walsh MF, Nichols KE, Porter CC (2024). Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy. Clin Cancer Res. ()
    2. Beigh M, Vagher J, Codden R, Maese LD, Cook S, Gammon A (2024). Newborn Screening for Li-Fraumeni Syndrome: Patient Perspectives. Res Sq. ()
    3. Fair D, Maese L, Chi YY, Li M, Hawkins DS, Venkatramani R, Rudzinski E, Parham D, Teot L, Malkin D, Plon SE, Li H, Sabo A, Lupo PJ, Schiffman JD (2023). TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report. Pediatr Blood Cancer, e30413. ()
    4. Foley M, Sharma A, Garfield K, Maese L, Buchmann L, Boyle J, Kohlmann W, Jeter J, Greenberg S (2022). A need to tailor surveillance based on family history: describing a highly penetrant familial paraganglioma kindred with an SDHD pathogenic variant. Fam Cancer, 22(2), 217-224. ()
    5. Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway KA (2024). Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol, 7, e2200334. ()
    6. Maese LD, Loh ML, Choi MR, Lin T, Aoki E, Zanette M, Agarwal S, Iannone R, Silverman JA, Silverman LB, Raetz EA, Rau RE (2022). Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.  . Blood, 141(7), 704-712. ()
    7. Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, Cherniack AD, Lindeman NI, Anderson ME, Cooney TM, Yeo KK, Reaman GH, DuBois SG, Collins NB, Johnson BE, Janeway KA, Forrest SJ (2022). Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol, 6, e2200390. ()
    8. MacFarland SP, Maese L, Rednam SP, Kamihara J, Perrino MR, Nichols KE, Brodeur GM, Schiffman JD, Plon SE, Diller LR, Malkin D, Porter CC, Villani A (2022). Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition. Cancer Prev Res (Phila), OF1-OF7. ()
    9. Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA (2022). Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med, 28(8), 1581-1589. ()
    10. Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E (2022). Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations (STARTRK-NG). Neuro Oncol, 24(10), 1776-1789. ()
    11. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey AT (2021). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clin Neurol Neurosurg, 212, 107064.
    12. Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard CC (2021). Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol.
    13. Iglesias Cardenas F, Agarwal AM, Vagher J, Maese L, Fluchel M, Afify Z (2020). Two Clonally Distinct B-Cell Lymphomas Reveal the Diagnosis of XLP1 in a Male Child and His Asymptomatic Male Relatives: Case Report and Review of the Literature. J Pediatr Hematol Oncol, 43(8), e1210-e1213. ()
    14. Maese L, Rizzari C, Coleman R, Power A, van der Sluis I, Rau RE (2021). Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? Pediatr Blood Cancer, 68(10), e29169. ()
    15. Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, Downie JM, Pei D, Cheng C, Gleason A, Luo M, Pui CH, Aplenc R, Hunger SP, Loh M, Greaves M, Trede N, Raetz E, Frazer JK, Mullighan CG, Engel ME, Miles RR, Rabin KR, Schiffman JD (2022). Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol, 7(10), 1521-1528. ()
    16. Bender C, Maese L, Carter-Febres M, Verma A (2021). Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. Blood Lymphat Cancer, 11, 25-40. ()
    17. Rower JE, King AD, Wilkins D, Wilkes J, Yellepeddi V, Maese L, Lemons RS, Constance JE (2020). Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer. J Adolesc Young Adult Oncol, 10(2), 175-184. ()
    18. Lozano-Chinga M, Draper L, George TI, Agarwal AM, Dansie DM, Maese L (2020). Bone marrow necrosis in pediatric malignancies: 10-Year retrospective review and review of literature. Pediatr Blood Cancer, 68(3), e28806. ()
    19. Olson J, Mehra S, Hersh AL, Thorell EA, Stoddard GJ, Maese L, Barnette PE, Lemons RS, Pavia AT, Knackstedt ED (2019). Oral Step-Down Therapy With Levofloxacin for Febrile Neutropenia in Children With Cancer. J Pediatric Infect Dis Soc, 10(1), 27-33. ()
    20. Kim J, Light N, Subasri V, Young EL, Wegman-Ostrosky T, Barkauskas DA, Hall D, Lupo PJ, Patidar R, Maese LD, Jones K, Wang M, Tavtigian SV, Wu D, Shlien A, Telfer F, Goldenberg A, Skapek SX, Wei JS, Wen X, Catchpoole D, Hawkins DS, Schiffman JD, Khan J, Malkin D, Stewart DR (2021). Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO Precis Oncol, 5. ()
    21. Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, Olshen A, Hechmer A, Aftandilian C, Bhat R, Choi SW, Chonat S, Farrar JE, Fluchel M, Frangoul H, Han JH, Kolb EA, Kuo DJ, MacMillan ML, Maese L, Maloney KW, Narendran A, Oshrine B, Schultz KR, Sulis ML, Van Mater D, Tasian SK, Hofmann WK, Loh ML, Stieglitz E (2020). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, Online ahead of print, 178-186. ()
    22. Hendrickson PG, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop AJ, Lloyd S, Kokeny KE, Hitchcock YJ, Poppe MM, Gaffney DK, Tao R (2020). Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study. Cancer Med, 9(21), 7954-7963. ()
    23. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, Rodriguez V, Rossoff J, Schuettpelz L, Silverman L, Sun J, Sun W, Teachey D, Wong V, Yanik G, Johnson-Chilla A, Ogba N (2020). Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(1), 81-112. ()
    24. Maese L, Raetz EA (2019). Can Ph-like ALL be effectively targeted? Best Pract Res Clin Haematol, 32(4), 101096. ()
    25. Hamilton KV, Maese L, Marron JM, Pulsipher MA, Porter CC, Nichols KE (2019). Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia? J Clin Oncol, 37(24), 2098-2104. ()
    26. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman JD (2019). Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatr Blood Cancer, 66(5), e27629. ()
    27. Maese L, Li KD, Xu X, Afify Z, Paxton CN, Putnam A (2017). Acute Leukemia and Concurrent Mediastinal Germ Cell Tumor: Case Report and Literature Review. Fetal Pediatr Pathol, 36(2), 168-176. ()

    Review

    1. Vagher J, Mehrhoff CJ, Florou V, Maese LD (2024). Genetic Predisposition to Sarcoma: What Should Clinicians Know? [Review]. Curr Treat Options Oncol, 25(6), 769-783. ()
    2. Maese LD, Pulsipher MA (2023). Blinatumomab Conundrum in Low-Risk Relapsed B-Cell ALL. [Review]. J Clin Oncol, 41(25), 4087-4092. ()
    3. Maese L, Rau RE (2022). Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. [Review]. Front Pediatr, 10, 902117. ()
    4. Vagher J, Dietz MS, Schiffman JD, Kohlmann W, Maese L (2022). Germline predisposition to soft tissue sarcoma. [Review]. J Cancer Metastasis Treat, 8. ()

    Letter

    1. Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker C (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. [Letter to the editor]. Br J Haematol, 198(6), e78-e81. ()

    Other

    1. Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J (2021). Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol (5). United States. ()

  • Clinical Trials